Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?
From Yahoo Finance: 2025-05-11 16:55:00
Jim Simons’ Renaissance Technologies identifies Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as one of the best stocks to buy. Simons’ data-driven strategies led to impressive returns, making him a billionaire. Renaissance’s funds continue to perform well, with the Diversified Alpha Fund gaining 9.05% and the Equities Fund rising 11.85%.
Vertex Pharmaceuticals (VRTX) is a global biotech company focused on developing medications for severe illnesses like cystic fibrosis. Despite narrowly missing Q1 earnings projections, the company remains optimistic about future growth. Analysts reiterate a $462 price target, urging patience amid a recent 10% share decline.
GreensKeeper Asset Management praises Vertex’s performance, citing growing demand for its Cystic Fibrosis franchise and the launch of new therapies. Vertex’s focus on diversification and innovative treatments like Alyftrek and Journavx positions it for success in the biotech industry. However, VRTX ranks 7th among top stocks, with other AI stocks showing more potential for higher returns.